References
Arciniegas, D. B. (2015). Psychosis. Retrieved April 5, 2018, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455840/pdf/20150600.0-0015.pdf
Avery, M. C., & Krichmar, J. L. (2017). Neuromodulatory Systems and Their Interactions: A Review of Models, Theories, and Experiments. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744617/pdf/fncir-11-00108.pdf
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H., Steiner, J., … & Gos, T. (2014). The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032934/pdf/fpsyt-05-00047.pdf
Dine, K. (2015). Neuroplasticity and Antipsychotics in Treatment of Schizophrenia. Retrieved from https://www.omicsonline.org/open-access/neuroplasticity-and-antipsychotics-in-treatment-of-schizophrenia-2329-6895-1000232.pdf
Hager, T. (2015). Seroquel (Quetiapine) An Easy-to-Read Guide to Uses, Benefits, Side Effects, Withdrawal, and More. Eugene, OR: Monroe Press.
Hilker R, Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, Nordentoft M, Glenthøj B. Heritability of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. Biol Psychiatry. 2018 Mar 15;83(6):492-498. doi: 10.1016/j.biopsych.2017.08.017. Epub 2017 Sep 1. PMID: 28987712.
Iasevoli, Felice, et al. “The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment.” Current Neuropharmacology, vol. 12, no. 3, 2014, pp. 219–238., doi:10.2174/1570159×12666140324183406.
Johnstone, EveC., et al. “CEREBRAL VENTRICULAR SIZE AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA.” The Lancet, vol. 308, no. 7992, 1976, pp. 924–926., doi:10.1016/s0140-6736(76)90890-4.
Kupfer, D. J., M.D., & Regier, D. A., M.D., M.P.H. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Retrieved from https://ia800805.us.archive.org/1/items/DSM-5/DSM-5.pdf
